Privacy Policy

This Data Policy explains how Syremis Therapeutics Ltd. (“Syremis”, “we”, “us”) collects and uses personal data through this website (“Website”).

PERSONAL DATA WE COLLECT

We collect information you voluntarily provide via contact or career forms (“Inquiry Information”), and limited technical data such as IP address, browser type, and usage data (“Analytics Information”). We do not collect clinical trial data or patient health data through the Website.

COOKIES

We use necessary cookies and, subject to consent, analytics and marketing cookies. Cookie preferences can be managed via the cookie banner.

HOW WE USE DATA

We use data to respond to inquiries, process job applications, operate and improve the Website, and comply with legal and regulatory obligations, including pharmacovigilance where applicable.

LEGAL BASES (EU)

Processing is based on legitimate interests, pre-contractual steps, legal obligations, or consent (where required).

INTERNATIONAL TRANSFERS

Data may be processed in Israel (recognized by the EU as adequate) and in other jurisdictions using appropriate safeguards.

DATA RETENTION & SECURITY

Data is retained only as necessary and protected using reasonable security measures.

CHILDREN

The Website is not intended for children under 16.

YOUR RIGHTS – EU & ISRAEL

You may request access, correction, deletion, or objection. Contact: info@syremis.com

YOUR RIGHTS – CALIFORNIA (CCPA/CPRA)

California residents may request disclosure, access, deletion, or correction of personal information, and may opt out of “sale” or “sharing” (Syremis does not sell personal data).

UPDATES

We may update this Policy periodically.

Reid Huber PhD
Partner, Third Rock Ventures

Reid Huber joined Third Rock in 2018 as a Partner, bringing more than 25 years of leadership and experience to the role. He focuses on the formation, development, and strategy of Third Rock’s portfolio companies. Reid served as Interim CEO of MOMA Therapeutics until the appointment of Dr. Asit Parikh in Spring of 2021, of Rapport Therapeutics until the appointment of Abe Ceesay in the Spring of 2023, and of Merida Biosciences until the appointment of Adam Townsend in the Spring of 2025.


Reid joined TRV from Incyte, where he was a member of the founding scientific team and most recently served as executive vice president and chief scientific officer. At Incyte, he held roles of increasing responsibility across multiple therapeutic areas in both drug discovery and clinical development. In 2011, he assumed responsibility for the company’s research and early development activities. Before joining Incyte, Reid held scientific research positions at DuPont Pharmaceuticals and Bristol-Myers Squibb from 1998 to 2002.


He received his Ph.D. in molecular genetics from the Washington University School of Medicine and held predoctoral and postdoctoral fellowships at the National Institutes 
of Health.


Reid is a board director at Rapport Therapeutics, Merida Biosciences, Terremoto, Synnovation Therapeutics, MOMA Therapeutics, Asher Biotherapeutics, and a board observer at insitro.